A clinical study on the safety of comprehensive therapy against hepatocarcinoma: combination of TAE and RFA , dendric cell - A clinical study on the safety of comprehensive therapy against hepatocarcinoma: combination of TAE and RFA , dendric cell

Juntendo University0 个研究点目标入组 3 人开始时间: 2019年3月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients must not have heart disorder, kidney disorder, respiratory disorder, hematopathy, clotting disorder, or other serious complication. 2) Patients must not be HIV positive. 3) Patients must not have carcinoma nor immunodeficiency in past history. 4) Patients must not have splenectomy nor splen radiation in past history. 5) Patients must not have allo organ transplantation in past history. 6) Patients must not subjected to continuous whole body administration of adrenal cortical steroid or antihistaminic. 7) Patients must have no surgery, chemotherapy nor radiation within 4 weeks before blood collection for treatment in this study. In addition, patients are also excluded if they have not recovered enough from those therapies above. 8) Female patients are excluded from the study when they are pregnant, possibly pregnant, or when they want to be pregnant or they are feeding. 9) Patients must be excluded when expected to be difficult to follow-up. 10) Patients must be excluded when principal investigator judge as inadequate.

发起方